Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial

Autor: Palle Jeppesen, Lars O. Dragsted, Jens F. Rehfeld, Mark Hvistendahl, Filip K. Knop, David P. Sonne, Hannelouise Kissow, Rahim M. Naimi, Jens Pedersen, Svend Høime Hansen

Publikováno v: Hvistendahl, M K, Naimi, R M, Hansen, S H, Rehfeld, J F, Kissow, H, Pedersen, J, Dragsted, L O, Sonne, D P, Knop, F K & Jeppesen, P B 2022, ' Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial ', Journal of Parenteral and Enteral Nutrition, vol. 46, no. 4, pp. 923-935 . https://doi.org/10.1002/jpen.2224

Background: The gut-liver axis and enterohepatic circulation have gained increasing attention lately. Patients with short bowel syndrome (SBS) are, in fact, human knock-out models that may assist in the understanding of bile acid synthesis and regula

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582e8d37ea4bf89bff151071128c2732
https://pubmed.ncbi.nlm.nih.gov/34287979

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study

Autor: Hanna Johnsen, C. Christiansen, Lise Margrete Thomassen, Jens J. Holst, Mark Hvistendahl, Rahim M. Naimi, Bolette Hartmann, Palle Jeppesen

Publikováno v: BMJ Open Gastroenterology
BMJ Open Gastroenterology, Vol 8, Iss 1 (2021)
Naimi, R M, Hvistendahl, M K, Thomassen, L M, Johnsen, H, Christiansen, C B, Holst, J J, Hartmann, B & Jeppesen, P B 2021, ' Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity : an open-label pilot study ', BMJ Open Gastroenterology, vol. 8, no. 1, e000604 . https://doi.org/10.1136/bmjgast-2021-000604

ObjectivePatients with short bowel syndrome (SBS) and colon in continuity have better adaptation potential compared with patients with jejunostomy. Adaptation may involve enhanced postprandial secretion of the enteroendocrine hormones glucagon-like p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f59cddd4707f9b5a20fb2cb0839cc8a
https://pubmed.ncbi.nlm.nih.gov/33975891

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome:findings from a randomised phase 2 trial

Autor: Mark Hvistendahl, Nikolaj Nerup, Palle Jeppesen, Rahim M. Naimi, Holger Jon Møller, Hendrik Vilstrup, Henning Grønbæk, A Steensberg, Lars Bo Svendsen, Michael Patrick Achiam, Rikard Ambrus

Publikováno v: Naimi, R M, Hvistendahl, M, Nerup, N, Ambrus, R, Achiam, M P, Svendsen, L B, Grønbæk, H, Møller, H J, Vilstrup, H, Steensberg, A & Jeppesen, P B 2019, ' Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome : findings from a randomised phase 2 trial ', EBioMedicine, vol. 46, pp. 444-451 . https://doi.org/10.1016/j.ebiom.2019.07.016
EBioMedicine, Vol 46, Iss, Pp 444-451 (2019)
EBioMedicine

Background: With the introduction of glucagon-like peptide-2 (GLP-2) in the treatment of short bowel syndrome (SBS), there is emerging evidence that GLP-2 may play a role in the restoration of the disturbed homeostatic feedback in the gut-liver axis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05947bfad093b676693c358f7a35acb1
https://curis.ku.dk/portal/da/publications/effects-of-glepaglutide-a-novel-longacting-glucagonlike-peptide2-analogue-on-markers-of-liver-status-in-patients-with-short-bowel-syndrome(dada8f5d-ba75-473f-a1ee-648f2566f6a1).html

Home Parenteral Nutrition in Adult Patients With Chronic Intestinal Failure: The Evolution Over 4 Decades in a Tertiary Referral Center

Autor: Mark Hvistendahl, Siri Tribler, Christopher F. Brandt, Michael Staun, Rahim M. Naimi, Per Brøbech, Palle Jeppesen

Publikováno v: Journal of Parenteral and Enteral Nutrition. 41:1178-1187

In Denmark, the public healthcare system ensures patients with intestinal failure (IF) the same rights for a life-saving treatment as patients with other organ failures. This study reports the epidemiological data from the largest Danish IF center. A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545249d26c03a7ddd7a357af6a1eeece
https://doi.org/10.1177/0148607116655449

Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on hepatic function as measured by transient elastography and indocyanine green clearance in patients with short bowel syndrome

Autor: Palle Jeppesen, Lars Bo Svendsen, Rikard Ambrus, Michael Patrick Achiam, Linea Landgrebe Ring, Mark Hvistendahl, Rahim M. Naimi, Mark Berner Hansen, Nikolaj Nerup

Publikováno v: Clinical Nutrition. 37:S35-S36

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07a0bf8ff0d54d1f8760609f67f06348
https://doi.org/10.1016/j.clnu.2018.06.1177